The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Open accessAbstract
BACKGROUND: mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity in early studies. METHODS: -mutated cancer. Secondary end points included overall response and safety. RESULTS: -mutated cancer was greater with alpelisib-fulvestrant than with placebo-fulvestrant (26.6% vs. 12.8%); among patients with measurable disease in this cohort, the percentages were 35.7% and 16.2%, respectively. In the overall population, the most frequent adverse events of grade 3 or 4 were hyperglycemia (36.6% in the alpelisib-fulvestrant group vs. 0.7% in the placebo-fulvestrant group) and rash (9.9% vs. 0.3%). Diarrhea of grade 3 occurred in 6.7% of patients in the alpelisib-fulvestrant group, as compared with 0.3% of those in the placebo-fulvestrant group; no diarrhea of grade 4 was reported. The percentages of patients who discontinued alpelisib and placebo owing to adverse events were 25.0% and 4.2%, respectively. CONCLUSIONS: -mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Only 20 patients (6%) in SOLAR-1 had been previously exposed to a CDK4/6 inhibitor.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the use of which as a single-agent is now suboptimal in the second line”
From Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperglycemia occurs early during therapy (median time of onset of about 2 weeks from initiation of alpelisib) with an incidence of $60% overall and typically resolves upon treatment cessation (220-222).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the PIK3CA-mutated cohort, alpelisib provided a PFS benefit of 11.0 months versus 5.7 months [hazard ratio (HR) for progression or death: 0.65; 95% confidence interval (CI) 0.50-0.85, P < 0.001].”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“Toxicity was substantially increased in the alpelisib arm, especially hyperglycaemia, rash, gastrointestinal (GI) complaints (nausea, vomiting, loss of appetite, mucositis, diarrhoea) and fatigue, which lead to dose reductions/interruptions in around 70% of patients and discontinuations in 25%.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J. C. S., Bhattacharyya, G. S., Biganzoli, L., Cardoso, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,046
Self-citationUS Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A. G., & Cronin, K. A. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju055 · Cited by 1,572
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Lopez, B. A., Barrios, C. H., Bergh, J. C. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,194
Self-citationO’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Self-citationRugo, H. S., Rumble, R. B., Macrae, E. R., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L. J., Fowble, B. F., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 640
Self-citationConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationMiller, T. W., Hennessy, B. T., Gonzalez-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., Garcı́a-Echeverrı́a, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 555
Baselga, J. M., Im, S., Iwata, H., Cortés, J., Laurentiis, M. D., Jiang, Z., Arteaga, C. L., Jonat, W., Clemons, M. J., Ito, Y., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30376-5 · Cited by 538
Self-citationFritsch, C. M., Huang, A., Chatenay‐Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D. A., Erdmann, D., Pover, A. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0865 · Cited by 504
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Juric D, Janku F, Rodón J, et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol 2018 December 13 (Epub ahead of print).30543347
- Juric D Ciruelos E Rubovszky G et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Presented at the San Antonio Breast Cancer Symposium San Antonio TX December 4–8 2018. abstract.
Cited by
Sorted by citations
Items 301–400 of 1,004
Tannock, I. F., Pond, G. R., & Booth, C. M. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8206 · Cited by 57
Accelerating drug development in breast cancer: New frontiers for ER inhibition
Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57
Stergiopoulou, D., Markou, A. N., Strati, A. D., Zavridou, M., Tzanikou, E., Mastoraki, S., Kallergi, G., Georgoulias, V., & Lianidou, E. S. (2023) · Scientific Reports · doi:10.1038/s41598-022-25400-1 · Cited by 57
Rej, R. K., Roy, J., & Allu, S. R. (2024) · Cancers · doi:10.3390/cancers16030552 · Cited by 65
Immunometabolism in cancer: basic mechanisms and new targeting strategy
Su, R., Shao, Y., Huang, M., Liu, D., Yu, H., & Qiu, Y. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02006-2 · Cited by 62
Precision medicine in breast cancer: From clinical trials to clinical practice
Crimini, E., Repetto, M., Aftimos, P. G., Botticelli, A., Marchetti, P., & Curigliano, G. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102223 · Cited by 58
M.S, D. M. B., Phillips, G. S., Geisler, A. N., Trelles, S., Markova, A., Noor, S. J., Quigley, E. A., Haliasos, H. C., Moy, A. P., Schram, A. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.016 · Cited by 58
Rathinaswamy, M. K., Gaieb, Z., Fleming, K. D., Borsari, C., Harris, N. J., Moeller, B. E., Wymann, M. P., Amaro, R. E., & Burke, J. E. (2021) · eLife · doi:10.7554/elife.64691 · Cited by 54
PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib
Chan, C.-H., Chiou, L.-W., Lee, T.-Y., Liu, Y.-R., Hsieh, T.-H., Yang, C.-Y., & Jeng, Y.-M. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02032-w · Cited by 56
Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Ishida, Y., Kakiuchi, N., Yoshida, K., Inoue, Y., Irie, H., Kataoka, T. R., Hirata, M., Funakoshi, T., Matsushita, S., Hata, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3205 · Cited by 55
Mollon, L. E., Anderson, E. J., Dean, J. L., Warholak, T. L., Aizer, A. A., Platt, E., Tang, D. H., & Davis, L. E. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.08.011 · Cited by 55
Zhong, F., Wu, X., Yang, R., Li, X., Wang, D., Fu, Z., Liu, X., Wan, X., Yang, T., Fan, Z., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00885-0 · Cited by 55
Bardia, A., Chandarlapaty, S., Linden, H. M., Ulaner, G. A., Gosselin, A., Cartot‐Cotton, S., Cohen, P., Doroumian, S., Paux, G., Celanovic, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31668-8 · Cited by 55
Self-citationCDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Zhou, F. H., Downton, T. D., Freelander, A., Hurwitz, J., Caldon, C. E., & Lim, E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1148792 · Cited by 58
Targeting triple-negative breast cancer: A clinical perspective
POPOVIC, L. S., Matovina-Brko, G., Popovic, M., Punie, K., Cvetanović, A., & Lambertini, M. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028525 · Cited by 57
R�os, S., Wright, A. J., D’Santos, P., Hu, D., Hesketh, R. L., Lubling, Y., Georgopoulou, D., Lerda, G., Couturier, D., Razavi, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.016 · Cited by 55
Therapeutic strategies of different HPV status in Head and Neck Squamous Cell Carcinoma
Sun, Y., Wang, Z., Qiu, S., & Wang, R. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58077 · Cited by 54
Gerratana, L., Davis, A. A., Zhang, Q., Basile, D., Rossi, G., Strickland, K. S., Franzoni, A., Allegri, L., Mu, Z., Zhang, Y., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00345 · Cited by 54
Tankova, T. I., Senkus, E., Beloyartseva, M., Borštnar, S., Catrinoiu, D., Фролова, М. А., Hegmane, A., Janež, A., Krnić, M., Lengyel, Z., et al. (2022) · Cancers · doi:10.3390/cancers14071598 · Cited by 60
Self-citationFuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 55
Matsubara, J., Mukai, K., Kondo, T., Yoshioka, M., Kage, H., Oda, K., Kudo, R., Ikeda, S., Ebi, H., Muro, K., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.23336 · Cited by 55
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Amato, O., Giannopoulou, N., & Ignatiadis, M. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00626-6 · Cited by 64
Trop2-targeted therapy in breast cancer
Hu, Y., Zhu, Y., Qi, D., Tang, C., & Zhang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00633-6 · Cited by 54
Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
Papadopoulou, E., Τσούλος, Ν., Tsantikidi, K., Metaxa-Mariatou, V., Stamou, P. E., Kladi-Skandali, A., Kapeni, E., Tsaousis, G., Pentheroudakis, G. E., Petrakis, D., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226853 · Cited by 55
Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
Al-Mahayri, Z. N., Patrinos, G. P., & Ali, B. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00445 · Cited by 54
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 56
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer
Liu, H., Paddock, M. N., Wang, H., Murphy, C. J., Geck, R. C., Navarro, A. J., Wulf, G. M., Elemento, O., Haucke, V., Cantley, L. C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1262 · Cited by 56
Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, E. M., Smith, K. L., & Stearns, V. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.010 · Cited by 57
Marazzi, F., Orlandi, A., Manfrida, S., Masiello, V., Leone, A. D., Massaccesi, M., Moschella, F., Franceschini, G., Bria, E., Gambacorta, M. A., et al. (2020) · Cancers · doi:10.3390/cancers12092390 · Cited by 52
Xiao, W., Zhang, G., Chen, B., Chen, X., Wen, L., Lai, J., Li, X., Li, M., Liu, H., Liu, J. L., et al. (2021) · Journal of Cancer · doi:10.7150/jca.52993 · Cited by 53
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Sochacka-Ćwikła, A., Mą̨czyński, M., & Regiec, A. (2022) · Molecules · doi:10.3390/molecules27072259 · Cited by 56
Navarro-Yepes, J., Kettner, N. M., Rao, X., Bishop, C. S., Bui, T. N., Wingate, H. F., Raghavendra, A. S., Wang, Y., Wang, J., Şahin, A. A., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0705 · Cited by 55
Oncogenic activation of PIK3CA in cancers: Emerging targeted therapies in precision oncology
Wang, Y., Rozen, V., Zhao, Y., & Wang, Z. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101430 · Cited by 60
Markou, A. N., Tzanikou, E., Ladas, I., Makrigiorgos, G. M., & Lianidou, E. S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03325 · Cited by 53
Jacob, S. L., Davis, A. A., Gerratana, L., Velimirovic, M., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1566 · Cited by 56
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113473 · Cited by 53
Bertucci, F., Finetti, P., Gonçalvès, A., & Birnbaum, D. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0151-5 · Cited by 52
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Luen, S. J., Viale, G., Nik‐Zainal, S., Savas, P. S., Kammler, R., Dell’Orto, P., Biasi, O., Degasperi, A., Brown, L. C., Láng, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.009 · Cited by 52
Self-citationOmics Technologies Improving Breast Cancer Research and Diagnostics
Orsini, A., Diquigiovanni, C., & Bonora, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612690 · Cited by 52
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 67
Clinical implications of prospective genomic profiling of metastatic breast cancer patients
van Geelen, C. T., Savas, P. S., Teo, Z. L., Luen, S. J., Weng, C.-F., Ko, Y.-A., Kuykhoven, K. S., Caramia, F., Salgado, R., Francis, P. A., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01328-0 · Cited by 52
Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1924150 · Cited by 52
Marret, G., Bièche, I., Dupain, C., Borcoman, É., du Rusquec, P., Ricci, F., Hescot, S., Sablin, M., Tresca, P., Bello, D., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00280 · Cited by 54
The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
Majumder, A., Sandhu, M., Banerji, D., Steri, V., Olshen, A. B., & Moasser, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-88683-w · Cited by 52
The molecular tumor burden index as a response evaluation criterion in breast cancer
Yi, Z., Ma, F., Rong, G., Liu, B., Guan, Y., Li, J., Sun, X., Wang, W., Guan, X., Mo, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00662-9 · Cited by 53
Servetto, A., Formisano, L., & Arteaga, C. L. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188595 · Cited by 50
Layman, R. M., Han, H. S., Rugo, H. S., Stringer-Reasor, E. M., Specht, J. M., Dees, E. C., Kabos, P., Suzuki, S., Mutka, S. C., Sullivan, B. F., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00034-2 · Cited by 55
Self-citationGenomic alterations in STK11 can predict clinical outcomes in cervical cancer patients
Hirose, S., Murakami, N., Takahashi, K., Kuno, I., Takayanagi, D., Asami, Y., Matsuda, M., Shimada, Y., Yamano, S., Sunami, K., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.10.022 · Cited by 51
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 52
Lodrini, M., Graef, J., Thole-Kliesch, T. M., Astrahantseff, K., Sprüssel, A., Grimaldi, M., Peitz, C., Linke, R. B., Hollander, J. F., Lankes, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3716 · Cited by 54
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study
Valachis, A., Carlqvist, P., Ma, Y., Szilcz, M., Freilich, J., Vertuani, S., Holm, B., & Lindman, H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01845-z · Cited by 50
Damodaran, S., O'Sullivan, C. C., Elkhanany, A. M., Anderson, I. C., Barve, M. A., Blau, S. H., Cherian, M. A., Peguero, J. A., Goetz, M. P., Plourde, P. V., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3103 · Cited by 50
Jhaveri, K. L., Lim, E., Jeselsohn, R. M., Ma, C. X., Hamilton, E. P., Osborne, C. R. C., Bhave, M. A., Kaufman, P. A., Beck, J. T., Manso, L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02733 · Cited by 52
Self-citationSmyth, L. M., Zhou, Q. C., Nguyen, B., Yu, C., Lepisto, E. M., Arnedos, M., Hassett, M. J., Lenoue-Newton, M. L., Blauvelt, N., Doğan, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1209 · Cited by 50
Self-citationNagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 51
Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer
Freelander, A., Brown, L. J., Parker, A. J., Segara, D., Portman, N., Lau, B., & Lim, E. (2021) · Genes · doi:10.3390/genes12020285 · Cited by 52
Palmieri, C., Linden, H. M., Birrell, S. N., Wheelwright, S. J., Lim, E., Schwartzberg, L. S., Dwyer, A. R., Hickey, T. E., Rugo, H. S., Cobb, P. W., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00004-4 · Cited by 50
Self-citationBrowne, I. M., & Okines, A. F. C. (2024) · Cancers · doi:10.3390/cancers16122259 · Cited by 53
Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations
Ge, J., Yin, X., & Chen, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457189 · Cited by 52
Bos, M. K., Angus, L., Nasserinejad, K., Jager, A., Jansen, M. P. H. M., Martens, J. W. M., & Sleijfer, S. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101951 · Cited by 51
Vernieri, C., Corti, F., Nichetti, F., Ligorio, F., Manglaviti, S., Zattarin, E., Rea, C. G., Capri, G., Bianchi, G., & de Braud, F. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01271-0 · Cited by 51
Lee, K., Zotano, Á. G., Servetto, A., Sudhan, D. R., Lin, C.-C. A., Formisano, L., Jansen, V. M., Ericsson, P. I. G., Sanders, M. E., Stricker, T. P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19291-x · Cited by 48
The emerging relationship between metabolism and DNA repair
Cucchi, D., Gibson, A., & Martin, S. A. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1912889 · Cited by 55
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
Vitale, S. R., Martorana, F., Stella, S., Motta, G., Inzerilli, N., Massimino, M., Tirrò, E., Manzella, L., & Vigneri, P. G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103334 · Cited by 47
Davis, A. A., Luo, J. R., Zheng, T., Dai, C., Dong, X., Tan, L., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2177 · Cited by 50
Liquid Biopsy: The Challenges of a Revolutionary Approach in Oncology
Coppola, C. A., Summa, S. D., Matera, G., Pilato, B., Traversa, D., & Tommasi, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115013 · Cited by 52
Comparison of methods for the isolation of cell-free DNA from cell culture supernatant
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2020) · Tumor Biology · doi:10.1177/1010428320916314 · Cited by 48
Mouron, S. A., Manso, L., Caleiras, E. J., Rodríguez‐Peralto, J. L., Rueda, O. M., Caldas, C., Colomer, R., Quintela-Fandiño, M., & Bueno, M. J. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01398-8 · Cited by 50
Liu, D., Weintraub, M. A., Garcia, C., Goncalves, M. D., Sisk, A. E., Casas, A., Harding, J. J., Harnicar, S. J., Drilon, A. E. D. C., Jhaveri, K. L., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4579 · Cited by 47
Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
Hall, D. C. N., & Benndorf, R. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04430-y · Cited by 48
Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth
Wenger, T. L., Ganti, S. N., Bull, C. V., Lutsky, E., Bennett, J. T., Zenner, K., Jensen, D. M., Dmyterko, V., Mercan, E., Shivaram, G. M., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.07.026 · Cited by 47
Colomer, R., González‐Farré, B., Ballesteros, A. I., Peg, V., Bermejo, B., Perez‐Mies, B., de la Cruz, S., Rojo, F., Pernas, S., & Palacios, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03541-1 · Cited by 55
Associations between Diabetes Mellitus and Selected Cancers
Pliszka, M., & Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137476 · Cited by 53
The paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan, E. A., Wallis, R., Mossa, F., & Bishop, C. L. (2024) · npj Aging · doi:10.1038/s41514-024-00168-y · Cited by 50
Şahin, T. K., Rizzo, A., Güven, D. C., & Aksoy, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102924 · Cited by 48
Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function
Rouhimoghadam, M., Lu, A. S., Salem, A. K., & Filardo, E. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.591217 · Cited by 49
Migliaccio, I., Bonechi, M., McCartney, A., Guarducci, C., Benelli, M., Biganzoli, L., Leo, A. D., & Malorni, L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102136 · Cited by 50
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Self-citationKarlstaedt, A., Barrett, M., Hu, R., Gammon, S. T., & Ky, B. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.05.008 · Cited by 48
The Way of the Future: Personalizing Treatment Plans Through Technology
Liefaard, M. C., Lips, E. H., Wesseling, J., Hylton, N. M., Lou, B., Mansi, T., & Pusztai, L. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320593 · Cited by 48
Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
Huang, R. S. P., Harries, L., Decker, B. J., Hiemenz, M., Murugesan, K., Creeden, J., Tolba, K. A., Stabile, L. P., Ramkissoon, S. H., Burns, T. F., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac094 · Cited by 47
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer
Kingston, B., Pearson, A., Herrera-Abreu, M. T., Sim, L.-X., Cutts, R. J., Shah, H. P., Moretti, L., Kilburn, L., Johnson, H., Macpherson, I. R., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1387 · Cited by 44
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity
Passarelli, A. M., Carbone, V., Pignata, S., Mazzeo, R., Lorusso, D., Scambia, G., Canova, S., Palma, T. D., Tasca, G., Mantiero, M., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.02.029 · Cited by 46
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Gupta, A., Gazzo, A. M., Selenica, P., Safonov, A. M., Pareja, F. G., da Silva, E. M., Brown, D. N., Shao, H., Zhu, Y., Patel, J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02187-1 · Cited by 51
M.S, D. M. B., Phillips, G. S., Freites‐Martínez, A., Hsu, M., Ciccolini, K. T., Lucas, A. S., Marchetti, M. A., Rossi, A. M., Lee, E. H., Deng, L., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16159 · Cited by 46
Kalofonou, M., Malpartida-Cardenas, K., Alexandrou, G., Rodríguez-Manzano, J., Yu, L., Miscourides, N., Allsopp, R. C., Gleason, K. L. T., Goddard, K., Fernández-García, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60852-3 · Cited by 47
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
Batalini, F., Moulder, S., Winer, E. P., Rugo, H. S., Lin, N., & Wulf, G. M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00403 · Cited by 46
Self-citationCATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 47
Dumbrava, E. E. I., Call, S. G., Huang, H. J., Stuckett, A. L., Madwani, K., Adat, A., Hong, D. S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100230 · Cited by 46
Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation
Liu, X., Yang, S., Hart, J. R., Xu, Y., Zou, X., Zhang, H., Zhou, Q., Xia, T., Zhang, Y., Yang, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109327118 · Cited by 45
Bruno, L. I., Ostinelli, A., Waisberg, F., Enrico, D. H., Ponce, C., Rivero, S. G., Blanco, A., Zarbá, M., Loza, M., Fabiano, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00140 · Cited by 49
Sivakumar, S., Jin, D. X., Tukachinsky, H., Murugesan, K., McGregor, K., Danziger, N. A., Pavlick, D. C., Gjoerup, O. V., Ross, J. S., Harmon, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35245-x · Cited by 47
AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis
Sun, Z., Jiang, Q., Gao, B. X., Zhang, X., Bu, L., Wang, L., Lin, Y., Xie, W., Li, J., & Guo, J. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3407 · Cited by 45
Ma, J., Chan, J. J., Toh, C. H., & Yap, Y. S. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00578-3 · Cited by 49
Jhaveri, K. L., & Marmé, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102670 · Cited by 49
The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances
Khorasani, A. B. S., Hafezi, N., Sanaei, M., Jafari‐Raddani, F., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3998 · Cited by 47
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Wang, H., Tang, R., Ling, J., & Jia, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1494802 · Cited by 50
Mutant SF3B1 promotes AKT- and NF-κB–driven mammary tumorigenesis
Liu, B., Liu, Z., Chen, S., Ki, M., Erickson, C., Reis-Filho, J. S., Durham, B. H., Chang, Q., de Stanchina, E., Sun, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138315 · Cited by 49
Rozenblit, M., Mun, S., Soulos, P. R., Adelson, K. B., Pusztai, L., & Mougalian, S. S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01394-y · Cited by 45
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
Thibault, B., Ramos‐Delgado, F., Tostivint, E. P., Therville, N., Cintas, C., Arcucci, S., Cassant‐Sourdy, S., Reyes‐Castellanos, G., Tosolini, M., Villard, A. V., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013502 · Cited by 46
Metadata
- Authors
- André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y.-S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A.-S., Mills, D., Wilke, C., Hirawat, S., & Juric, D.
- Affiliations
- Université Paris-Sud (FR)
- From Institut Gustave Roussy, INSERM Unité 981, Université Paris-Sud, Villejuif (F.A.), Institut de Cancérologie de l’Ouest, St. Herblain (M.C.), and Novartis Pharma, Paris (A.-S.L.) — all in France; Hospital Universitario 12 de Octubre, Madrid (E.C.); National Institute of Oncology (G.R.) and Duna Medical Center (Z.P.), Budapest, Hungary; German Breast Group, Neu-Isenburg, and Center for Hematology and Oncology Bethanien, Frankfurt — both in Germany (S.L.); UCSF Helen Diller Family Comprehensive...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-05-16
- Volume
- 380
- Issue
- 20
- Pages
- 1929-1940
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2945564879
- Cited by
- 2,622
- References
- 25
- Citations by year
- 2026: 314 · 2025: 356 · 2024: 370 · 2023: 329 · 2022: 375 · 2021: 450 · 2020: 345 · 2019: 81
- FWCI
- 231.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Hispana (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Funders
- Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- alpelisib, PIK3CA mutation, hormone receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, PI3Kα inhibitor, fulvestrant, endocrine therapy, hyperglycemia, diarrhea, adverse events
- MeSH terms
- Fulvestrant, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Diarrhea, Female, Humans, Middle Aged, Mutation, Receptors, Estrogen, Receptors, Progesterone, Thiazoles, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
